Relmada Therapeutics, Inc.

罗森律师事务所宣布一项代表Relmada Therapeutics, Inc. (NASDAQ: RLMD) 的投资人对该公司潜在的集体诉讼请求发起调查。该调查缘起于对Relmada 可能向投资公众发布了具有重大误导性的商业信息的指控。

如果您购买了Relmada 股票,并且您想参加此次集体诉讼的话,请点击“加入此集体行动”键。


如果您购买了 Relmada 证券,您可能有权获得赔偿,而无需支付任何自付费用或通过应急费用安排产生的费用。

Details of investigation:

2022 年 10 月 13 日,Relmada 公布了其 RELIANCE III 研究(REL-1017-303)的结果,评估药物 REL-1017 作为重度抑郁症(MDD)的单一疗法。 该公司透露,RELIANCE III 试验未达到其主要终点,即根据 Mongomery-Asberg 抑郁量表( MADRS )测量,与安慰剂相比,第28天抑郁症状有统计学意义的显着改善。 具体而言,REL-1017 治疗显示第 28 天的 MADRS 降低了 14.8 分,而安慰剂组为 13.9 分,高于预期的安慰剂反应。Relmada 描述说,“在某些研究地点观察到了自相矛盾的结果,其中安慰剂的表现显着优于 REL-1017。”

本消息导致Relmada 股价在 2022 年 10 月 13 日每股下跌 25.22 美元,或 79.57%,收于每股 6.4750 美元。

Follow us on:
Company Name: Relmada Therapeutics, Inc.
Stock Symbol: RLMD
Class Period: N/A
Court: N/A

Why Rosen Law

The Rosen Law Firm has been ranked among the top 4 law firms each year since 2013 for the number of successful securities class actions on behalf of investors. In 2019 alone, our firm recovered $438 million for investors.

Investors should carefully identify and select experienced counsel with a track record of success leading securities class actions. Often other firms issue press releases about class actions yet do not have comparable experience or resources.

Institutional Shareholders Services ranked the Rosen Law Firm # 1 for the number of securities class action recoveries in 2017.

The Rosen Law Firm represents investors throughout the globe. Our mission is to prosecute securities fraud class actions and protect shareholders’ rights.

Scroll to Top